Indeed, the treatment of SH-SY5Y neuroblastoma cells stably expressing GFP-0N4R Tau with the selective SETD7 inhibitor (R)-PFI-2 [29] significantly reduced both meK132- and meK130-modified Tau (Fig. 5a-b). The gene discussed is MAPT; the disease is neuroblastoma.